SanegeneBio Partners with Eli Lilly in $1.2 Billion RNAi Collaboration for Metabolic Diseases
核心洞察
SanegeneBio (搜索) announced a global research and licensing collaboration with Eli Lilly to advance RNAi therapeutics for metabolic diseases using the company's proprietary LEAD™ tissue-selective delivery platform.
The collaboration leverages SanegeneBio (搜索)'s innovative technology that could enable breakthrough therapies administered subcutaneously as infrequently as twice per year for metabolic disorders.
Under the agreement terms, SanegeneBio (搜索) is eligible to receive up to $1.2 billion in milestone payments plus tiered royalties, with Lilly handling clinical development and commercialization responsibilities.
SanegeneBio (搜索), a clinical-stage biotechnology company, has entered into a global research and licensing collaboration with pharmaceutical giant Eli Lilly and Company to develop RNAi therapeutics for metabolic diseases. The partnership, announced on November 8, 2025, centers on SanegeneBio's proprietary tissue selective delivery technology, LEAD™ (Ligand and Enhancer Assisted Delivery).
Collaboration Structure and Responsibilities
Under the collaboration framework, SanegeneBio (搜索) will handle the discovery and identification of optimized LEAD™-based RNAi molecules for each program. Eli Lilly will then take responsibility for subsequent IND-enabling studies, clinical development, and commercialization of the resulting therapeutics.
The division of responsibilities leverages each company's core strengths, with SanegeneBio (搜索) contributing its innovative delivery platform expertise while Lilly provides its extensive clinical development and commercialization capabilities in metabolic diseases.
LEAD™ Platform Technology
SanegeneBio (搜索)'s LEAD™ platform represents a potentially transformative approach to RNAi therapeutic delivery. The technology has the potential to generate breakthrough therapies for metabolic diseases that could be administered subcutaneously as infrequently as twice per year, offering significant advantages in patient convenience and compliance.
The tissue-selective delivery capability of the LEAD™ platform addresses one of the key challenges in RNAi therapeutics - ensuring targeted delivery to specific tissues while minimizing off-target effects.
Financial Terms and Market Validation
The collaboration includes substantial financial commitments from Lilly. SanegeneBio (搜索) will receive an upfront payment and equity investment, with eligibility for near-term milestone payments. The total potential value of the agreement reaches up to $1.2 billion in discovery, development, regulatory, and commercial milestone payments, plus tiered royalties on future product sales.
"Partnering with Lilly represents a strong validation of our innovative and differentiated LEAD™ platform for tissue-selective delivery of RNAi medicines," said Weimin Wang, Chief Executive Officer and Founder of SanegeneBio (搜索). "We look forward to working closely with Lilly, a global leader in innovation for metabolic diseases, to unlock novel approaches for the treatment of metabolic disorders and to advance durable, disease-modifying therapies for patients worldwide."
Strategic Implications for Metabolic Disease Treatment
The collaboration positions both companies to address significant unmet needs in metabolic disease treatment through novel RNAi approaches. Lilly's established leadership in metabolic disease innovation, combined with SanegeneBio (搜索)'s specialized delivery technology, creates a platform for developing potentially transformative therapies.
The partnership reflects the growing recognition of RNAi therapeutics as a promising modality for treating metabolic disorders, particularly when combined with advanced delivery systems that can overcome traditional limitations of RNA-based medicines.